Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Example of details involved in acquisition talks: like ONCY

<< Previous

Bullboard Posts

Next >>

Comment by Angler101on Oct 11, 2023 6:05pm

131 Views

Post# 35679629

RE:RE:RE:Example of details involved in acquisition talks: like ONCY

Just think about how highly unlikely it is that the news will be bad......after all the excellent trial results we’ve had in multiple trials with collaborations with what, 4 or 5 big pharmas, and then PanCAN coming on board, not once but twice, which all but guarantees approval and then approval soon after in the second indication......does anybody really believe that now, all of a sudden we’re going to hear that Pela causes huge side effects and just doesn’t do anything?

<< Previous

Bullboard Posts

Next >>

Catch up with companies that got a Stanley Cup Playoffs boost